Lifecare ASA

Regulatory Filings • Mar 21, 2024

LIFE: The European Patent Office issues a new Lifecare patent

LIFE: The European Patent Office issues a new Lifecare patent

Bergen, Norway, March 21st, 2024: Today, Lifecare AS (LIFE), a clinical stage

medical sensor company developing the next generation Continuous Glucose

Monitor (CGM), announces that the European Patent Office (EPO) has notified

that they will grant for a new patent to Lifecare.

Reference is made to stock exchange notification November 8th, 2023, that EPO

intended to grant Lifecare a new patent. After final review this grant was

expected to be announced within 6 months.

The patent relates to chemistry compositions and method for preparing the

composition and use, specifically Lifecare's proprietary fluid composition

reactive to glucose. This active fluid enables monitoring of glucose in

Lifecares miniaturized sensor-technology, buy the means of osmotic pressure as

the sensing principle, affecting and improving:

* sensor lifetime; due to high liquid stability

* measurement response asymmetry; because the viscosity is mainly independent

of the glucose concentration,

* measurement sensitivity; due to optimal concentration and choice of

compounds.

Considering existing and granted patents for Lifecare's sensor technology, CEO

of Lifecare, Joacim Holter, comments that this will strengthen our commercial

position for accurate and continuous monitoring of glucose, for people and

pets with diabetes.

Lifecare applied for this patent in 2018 and after EPO's granting, it will

strengthen the company's technology protection until 2037. Detecting glucose

by the principle of osmotic pressure holds promise of a glucose

sensingtechnology that is suitable for both miniaturization and long-term

continuous monitoring in vivo without causing patient discomfort or reducing

quality of life.

- Existing continuous glucose measurement technologies are inconvenient,

complicated, costly, and have limited lifetime. The Sencell system together

with the active fluid composition according to the invention has advantageous

effect on sensor lifetime, measurement response time, and measurement

sensitivity, says Lifecare CSO, Prof. Dr. Dr. Med. Andreas Pfützner.

About us

Lifecare AS is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body.

Contacts

For further information, please contact:

Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs,

asle.wingsternes@lifecare.no, +47 41 61 42 52

This information has been submitted pursuant to the Securities Trading Act §

5-12 and MAR Article 19 no. 3. The information was submitted for publication

at 2024-03-21 08:00 CET.